AKT1 and schizophrenia: Furthermore, genetic and pharmacological manipulations of the AKT/GSK3 pathway affect dopaminergic signaling and schizophrenia-related behaviors (Beaulieu et al., 2004; Emamian et al., 2004; Gould et al., 2007).